By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today said that it expects to raise approximately $17.6 million through a public offering of 4.2 million shares of its common stock priced at $4.50 per share.

The Madison, Wis.-based molecular diagnostics firm said that if the underwriters of the offering exercise the option to purchase an additional 630,000 shares, it would receive total net proceeds of around $20.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.